New Insights into Young-Onset Bladder Cancer

 New Insights into Young-Onset Bladder Cancer

A groundbreaking genomic study on clinically advanced urothelial bladder cancer (CAUBC) in young-onset bladder cancer (YOUC) patients is reshaping our understanding of age-related tumor biology. Analyzing 9,411 cases, researchers discovered distinct genetic and mutational differences between younger (<50) and older (>50) patients, revealing key insights that could transform treatment strategies.
ASCO GU 2025 | An Alternative ADT Option for Patients with Metastatic Prostate Cancer: Transdermal Estrogen

ASCO GU 2025 | An Alternative ADT Option for Patients with Metastatic Prostate Cancer: Transdermal Estrogen

Androgen deprivation therapy (ADT) remains the cornerstone treatment for patients with metastatic prostate cancer. However, it is frequently associated with adverse effects such as vasomotor symptoms, including hot flashes, fatigue, and bone density loss, which significantly impact patients' quality of life. The rapid advancements in therapeutic strategies for advanced prostate cancer have led to investigations into alternative approaches. A study presented at the 2025 ASCO GU Annual Meeting introduced transdermal estrogen as a potential ADT alternative, offering a new option for metastatic prostate cancer patients.
ASCO GI 2025 | Dr. Jin Li: A New Era for Chemotherapy as the First Oral Paclitaxel Demonstrates Non-Inferiority to Intravenous Administration

ASCO GI 2025 | Dr. Jin Li: A New Era for Chemotherapy as the First Oral Paclitaxel Demonstrates Non-Inferiority to Intravenous Administration

The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI) took place from January 23 to 25 in San Francisco, bringing together the latest advancements in digestive tract oncology. Paclitaxel remains one of the most important chemotherapeutic agents for gastric cancer treatment. However, the traditional intravenous (IV) formulation has long been associated with significant adverse effects. Chinese researchers have continued to optimize the structure and formulation of paclitaxel, aiming for better efficacy and safety, ultimately leading to the successful development and approval of the world's first oral paclitaxel solution.
SABCS 2024 | Professor Matteo Lambertini: Optimizing Treatment Strategies for BRCA-Mutated Breast Cancer and Highlights of the SABCS Conference

SABCS 2024 | Professor Matteo Lambertini: Optimizing Treatment Strategies for BRCA-Mutated Breast Cancer and Highlights of the SABCS Conference

In the field of breast cancer, the treatment of patients with BRCA gene mutations has always been a research hotspot. Recently, at the SABCS conference, Professor Matteo Lambertini from the San Martino Hospital of the University of Genoa, Italy, shared the latest findings on the treatment of BRCA-mutated breast cancer in depth (abstract number: GS1-08). This study aims to explore the impact of risk-reducing surgeries (including prophylactic mastectomy and prophylactic salpingo-oophorectomy) on the survival outcomes of young patients with BRCA-mutated breast cancer. The researchers collected and analyzed data from 5,290 young patients with BRCA-mutated breast cancer from 109 centers worldwide, providing important evidence for the cancer risk management strategies of this specific patient population. Oncology Frontier interviewed Professor Matteo Lambertini on-site at the SABCS conference and invited him to share the highlights of the conference that he focused on.
ASCO GU 2025 | Professor Toni Choueiri on the Future of Casdatifan in Clear Cell Renal Cell Carcinoma

ASCO GU 2025 | Professor Toni Choueiri on the Future of Casdatifan in Clear Cell Renal Cell Carcinoma

The VHL-HIF pathway is one of the most commonly activated pathways in clear cell renal cell carcinoma (ccRCC). Loss of von Hippel-Lindau (VHL) gene function leads to the stabilization of hypoxia-inducible factors HIF-1α and HIF-2α, driving tumor growth and progression. The development of HIF-2α inhibitors, including belzutifan and casdatifan, has introduced new therapeutic strategies for ccRCC.At the 2025 ASCO GU Annual Meeting, Professor Toni Choueiri from Dana-Farber Cancer Institute presented phase I study results on casdatifan, offering insights into its clinical activity and potential role in renal cell carcinoma treatment.
SOHO 2024 | Dr. Jorge E. Cortes Interprets the ASC4FIRST Study, Aiding in the Optimization of First-line Treatment Options for Newly Diagnosed CML

SOHO 2024 | Dr. Jorge E. Cortes Interprets the ASC4FIRST Study, Aiding in the Optimization of First-line Treatment Options for Newly Diagnosed CML

The advent of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of chronic myeloid leukemia (CML), transforming its management into a chronic disease model and bringing patient life expectancy close to that of the general population. However, some patients experience treatment failure due to intolerance or insufficient response to at least two existing therapies, or the development of resistance, with consecutive changes in TKIs being associated with an increased risk of treatment failure. Patients with prior treatment intolerance, not achieving major molecular response (MMR) within two years, or with BCR-ABL gene mutations may develop resistance to current TKIs, increasing the risk of disease progression. Moreover, as treatment duration extends, patient demands for treatment tolerability increase. Balancing disease treatment with quality of life is particularly important for long-term survival. During the recent 12th Annual Meeting of the Society for Hematologic Oncology (SOHO 2024), "Hematology Frontier" had the honor of interviewing Dr. Jorge E. Cortes, Director of the Georgia Cancer Center at the Medical College of Georgia, who discussed the profound impact of Asciminib on current CML treatment patterns and future therapeutic landscapes, based on key findings from the ASC4FIRST study.